This was the ADR's second consecutive day of gains.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese ...

All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...

The move comes as the company faces ‘several challenges’ around the launching of medicines and timed out patents ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The launch of My Green Lab Certification 2.0 introduces enhanced tools and resources to drive measurable impact in ...

Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots ...